Prescription of betablockers in chronic cardiac failure: Results of a national enquiry of cardiologists;Prescription des β-bloquants dans l'insuffisance cardiaque chronique: Résultats d'une enquête nationale auprès des cardiologues

Archives des Maladies du Coeur et des Vaisseaux

Volumn 97, Issue 12, 2004, Pages 1236-1243

  Solal, A Cohen ^a   Johnson, N ^b  

^a BEAUJON HOSPITAL   (France)

^b Produits Roche   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CARVEDILOL;

CLINICAL PRACTICE; DRUG CONTRAINDICATION; FRANCE; HEART FAILURE; HUMAN; PRESCRIPTION; QUESTIONNAIRE; REVIEW;

ADRENERGIC BETA-ANTAGONISTS; ADULT; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FRANCE; HEART FAILURE, CONGESTIVE; HUMANS; MALE; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; QUESTIONNAIRES;

EID: 11144255006     PISSN: 00039683     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (23)

1. Delahaye F, Gevigney G. Épidémiologie de l'insuffisance cardiaque. Ann Cardiol Angeiol 2001; 50: 6-11.
2. Recommandations de la Société européenne de cardiologie et spécificités françaises concernant le diagnostic et le traitement de l'insuffisance cardiaque chronique. Juillière Y au nom du Comité d'experts. Arch Mal Cœur 2002; 95 (II): 54-9.
3. Task Force for the diagnosis and treatment of chronic heart failure, European Society of Cardiology. WJ Remme and K. Swedberg (co-chairmen). Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J 2001; 22: 1527-60.
4. Mac Murray J, Cohen-Solal A, Dietz R et al. Practical recommendations for the use of ACE inhibitors, beta-blockers and spironolactone in heart failure: putting guidelines into practice. Eur J Heart Fail 2001; 3: 495-502.
5. ACTION HF Council Guidelines for the management of chronic heart failure. Am J Cardiol 1999; 83 (2A): 1A-38A.
6. Cleland JG, Swedberg K, Follath F et al. The EuroHeart Failure survey programme - a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis. Eur Heart J 2003; 24: 442-63.
7. Cleland JG, Cohen-Solal A, Aguilar JC et al. Management of heart failure in primary care (the IMPROVEMENT of Heart Failure Programme): an international survey. Lancet 2002; 360: 1631-9.
8. Jullien G, Fraboulet JY, Poncelet P et al. Registre de l'insuffisance cardiaque en cardiologie libérale. Arch Mal Cœur 2001; 94: 1351-6.
9. Komajda M, Bouhour JB, Amouyel P et al. Ambulatory heart failure management in private practice in France. Eur J Heart Fail 2001; 3: 503-7.
10. RCP Kredex, metoprolol CR-XL et bisoprolol.
11. Packer M et al. for the US Carvédilol Heart Failure Study Group. The effect of carvédilol on morbidity and mortality in patients with chronic heart failure. N Enql J Med 1996; 334: 1349-55.
12. Packer M, Coats AJ, Fowler MB et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001; 344: 1651-8.
13. The CAPRICORN investigators. Effect of carvedilol on outcome after myocardial infarction in patients with left ventricular dysfunction: the CAPRICORN randomised trial. Lancet 2001; 357: 1385-90.
14. CIBIS 2 Investigators and committees. The cardiac insufficiency Bisoprolol Study II (CIBIS II): a randomised trial. Lancet 1999; 353: 9-13.
15. Anonymous. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL. Randomised Intervention Trial in Congestive Heart Failure (MERIT-HP). Lancet 1999; 353: 2001-7.
16. The BEST investigators. A trial of beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med 2001; 344: 1659-67.
17. Bristow MR, Gilbert EM, Abraham WT et al., for the MOCHA investigators. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. Circulation 1996; 94: 2807-16.
18. Packer M, Poole-Wilson PA, Armstrong PW et al., on the behalf of the ATLAS study group. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. Circulation 1999; 100: 2312-18.
19. Gregoratos G, Abrams J, Epstein AE et al. ACC/AHA/NASPE 2002 guideline update for implantation of cardiac pacemakers and antiarrhythmia device: a report of the ACC/AHA task force on practice guidelines (ACC/AHA/NASPE committee to update the 1998 pacemakers guidelines). Circulation 2002; 106: 1-17.
20. Cazeau S, Leclercq C, Lavergne T et al., for the MUSTIC study investigators. Effects of multisite biventricular pacing in patients with heart failure and intraventricular conduction delay. N Engl J Med 2001; 344: 873-80.
21. Cleland JGF, Daubert JC, Erdmann E et al. The CARE-HF study: rationale, design and end-points. Eur Heart J Fail 2001; 3: 481-9.
22. Wikstrand J, Hjalmarson A, Waagstein F et al. Dose of metoprolol CR/XL and clinical outcomes in patients with heart failure: analysis of the experience in metoprolol CR/XL randomized intervention trial in chronic heart failure (MERIT-HF). J Am Coll Cardiol 2002; 40: 491-8.
23. Poole-Wilson PA, Swedberg K, Cleland JG et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 2003; 362: 7-13.